Brief: Alvotech And Teva Announce U.S. FDA Approval Of Selarsdi™ (Ustekinumab-Aekn), Biosimilar To Stelara® (Ustekinumab)
16/04/2024 22:31
April 16 (Reuters) - Alvotech SA ALVO.O :
* ALVOTECH AND TEVA ANNOUNCE U.S. FDA APPROVAL OF SELARSDI™
(USTEKINUMAB-AEKN), BIOSIMILAR TO STELARA® (USTEKINUMAB)
* ALVOTECH SA - SELARSDI IS EXPECTED TO BE MARKETED IN U.S.
ON OR
AFTER FEBRUARY 21, 2025
* ALVOTECH SA: SELARSDI IS EXPECTED TO BE MARKETED IN U.S.
ON OR
AFTER FEBRUARY 21, 2025
* ALVOTECH SA - SELARSDI APPROVED FOR BOTH ADULT, PEDIATRIC
INDICATIONS, IS 2ND BIOSIMILAR APPROVED UNDER STRATEGIC
PARTNERSHIP BETWEEN ALVOTECH, TEVA
Source text for Eikon: ID:nGNXbB2gz2
Further company coverage: ALVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alvotech SA
See all newsBrief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Brief: Alvotech and Teva Secure U.S. Settlement Date For AVT06
India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar
Brief: UK High Court Rules In Favor Of Alvotech Paving Way For AVT06, Biosimilar To Eylea
U.S. STOCKS ON THE MOVE-Cummins, EPAM Systems, Qualcomm